United States - English - NLM (National Library of Medicine)

ranbaxy laboratories ltd. - acyclovir (unii: x4hes1o11f) (acyclovir - unii:x4hes1o11f) - acyclovir 200 mg - herpes zoster infections: acyclovir capsules, usp and acyclovir tablets, usp are indicated for the acute treatment of herpes zoster (shingles). genital herpes: acyclovir capsules, usp and acyclovir tablets, usp are indicated for the treatment of initial episodes and the management of recurrent episodes of genital herpes. chickenpox: acyclovir capsules, usp and acyclovir tablets, usp are indicated for the treatment of chickenpox (varicella). acyclovir is contraindicated for patients who develop hypersensitivity to acyclovir or valacyclovir.

Australia - English - Department of Health (Therapeutic Goods Administration)

ranbaxy australia pty ltd - amoxycillin trihydrate; amoxycillin -

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - amoxicillin trihydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - amoxicillin trihydrate -

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

bristol laboratories ltd - phenobarbital - oral tablet - 30mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

bristol laboratories ltd - phenobarbital - oral tablet - 60mg

Australia - English - Department of Health (Therapeutic Goods Administration)

ranbaxy australia pty ltd - meloxicam -

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - losartan potassium 100mg - film coated tablet - 100 mg - active: losartan potassium 100mg excipient: colloidal silicon dioxide isopropyl alcohol lactose magnesium stearate   methylene chloride microcrystalline cellulose   opadry white 20h58983 pregelatinised maize starch   purified talc - ranbaxy-losartan is indicated for the treatment of hypertension. ranbaxy-losartan is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death, stroke, and myocardial infarction in hypertensive patients with left ventricular hypertrophy ranbaxy-losartan is indicated for the treatment of heart failure in patients who cannot tolerate an ace inhibitor. switching patients with heart failure who are stable on an ace inhibitor to ranbaxy-losartan is not recommended. ranbaxy-losartan is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine, end stage renal disease (need for dialysis or renal transplantation) or death; and to reduce proteinuria.

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - losartan potassium 12.5mg - film coated tablet - 12.5 mg - active: losartan potassium 12.5mg excipient: colloidal silicon dioxide isopropyl alcohol lactose magnesium stearate   methylene chloride microcrystalline cellulose   opadry white 20h58983 pregelatinised maize starch   purified talc - ranbaxy-losartan is indicated for the treatment of hypertension. ranbaxy-losartan is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death, stroke, and myocardial infarction in hypertensive patients with left ventricular hypertrophy ranbaxy-losartan is indicated for the treatment of heart failure in patients who cannot tolerate an ace inhibitor. switching patients with heart failure who are stable on an ace inhibitor to ranbaxy-losartan is not recommended. ranbaxy-losartan is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine, end stage renal disease (need for dialysis or renal transplantation) or death; and to reduce proteinuria.

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - losartan potassium 25mg - film coated tablet - 25 mg - active: losartan potassium 25mg excipient: colloidal silicon dioxide isopropyl alcohol lactose magnesium stearate   methylene chloride microcrystalline cellulose   opadry white 20h58983 pregelatinised maize starch   purified talc - ranbaxy-losartan is indicated for the treatment of hypertension. ranbaxy-losartan is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death, stroke, and myocardial infarction in hypertensive patients with left ventricular hypertrophy ranbaxy-losartan is indicated for the treatment of heart failure in patients who cannot tolerate an ace inhibitor. switching patients with heart failure who are stable on an ace inhibitor to ranbaxy-losartan is not recommended. ranbaxy-losartan is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine, end stage renal disease (need for dialysis or renal transplantation) or death; and to reduce proteinuria.